Article ; Online: Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study.
Medicina intensiva
2022 Volume 46, Issue 4, Page(s) 179–191
Abstract: Objective: The objective of the study is to identify the risk factors associated with mortality at six weeks, especially by analyzing the role of antivirals and munomodulators.: Design: Prospective descriptive multicenter cohort study.: Setting: ... ...
Abstract | Objective: The objective of the study is to identify the risk factors associated with mortality at six weeks, especially by analyzing the role of antivirals and munomodulators. Design: Prospective descriptive multicenter cohort study. Setting: 26 Intensive care units (ICU) from Andalusian region in Spain. Patients or participants: Consecutive critically ill patients with confirmed SARS-CoV-2 infection were included from March 8 to May 30. Interventions: None. Variables: Variables analyzed were demographic, severity scores and clinical condition. Support therapy, drug and mortality were analyzed. An univariate followed by multivariate Cox regression with propensity score analysis was applied. Results: 495 patients were enrolled, but 73 of them were excluded for incomplete data. Thus, 422 patients were included in the final analysis. Median age was 63 years and 305 (72.3%) were men. ICU mortality: 144/422 34%; 14 days mortality: 81/422 (19.2%); 28 days mortality: 121/422 (28.7%); 6-week mortality 152/422 36.5%. By multivariable Cox proportional analysis, factors independently associated with 42-day mortality were age, APACHE II score, SOFA score at ICU admission >6, Lactate dehydrogenase at ICU admission >470U/L, Use of vasopressors, extrarenal depuration, %lymphocytes 72h post-ICU admission <6.5%, and thrombocytopenia whereas the use of lopinavir/ritonavir was a protective factor. Conclusion: Age, APACHE II, SOFA>value of 6 points, along with vasopressor requirements or renal replacement therapy have been identified as predictor factors of mortality at six weeks. Administration of corticosteroids showed no benefits in mortality, as did treatment with tocilizumab. Lopinavir/ritonavir administration is identified as a protective factor. |
---|---|
MeSH term(s) | COVID-19 ; Cohort Studies ; Critical Illness ; Female ; Hospital Mortality ; Humans ; Infant ; Lopinavir/therapeutic use ; Male ; Middle Aged ; Prospective Studies ; Ritonavir/therapeutic use ; SARS-CoV-2 |
Chemical Substances | Lopinavir (2494G1JF75) ; Ritonavir (O3J8G9O825) |
Language | English |
Publishing date | 2022-02-21 |
Publishing country | Spain |
Document type | Journal Article ; Multicenter Study |
ISSN | 2173-5727 |
ISSN (online) | 2173-5727 |
DOI | 10.1016/j.medine.2021.02.008 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.